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ABSTRACT
We estimated the costs of Option B+ for HIV-infected pregnant women
in 12 facilities in Morogoro Region, Tanzania, from a provider
perspective. Costs of prevention of mother-to-child (PMTCT) HIV
services were measured over 12 months to September 2017 to
estimate the average costs per HIV testing episode, per HIV-positive
case diagnosed, per patient-year on antiretroviral therapy (ART), and
per neonatal HIV care. A one-way sensitivity analysis was undertaken
to understand how staffing levels and other core resource inputs
affected costs. The total number of HIV testing episodes was 25,593
with 279 HIV cases identified yielding a 1.1% positivity rate. The
average cost per testing episode was US$5.49 (range US$2.13 to US
$13.93), and the average cost per HIV case detected was US$503.29
(range US$230.61 to US$3330.38). The number of pregnant women
initiated on ART was 278. The mean cost per patient-year on ART
was US$159.89 (range US$100.91 to US$812.23). The average cost of
neonatal HIV care was US$90.09 (range US$41.53 to US$180.26).
PMTCT service costs varied widely across facilities due to variations
in resource use, number of women testing, and HIV prevalence. The
study provides further evidence against generalising cost estimates,
and that budgeting and planning requires context specific cost
information.
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The provision of anti-retroviral treatment (ART) to pregnant women based on CD4 cell count and
clinical staging (e.g. Options A and B), contributed to a global decline in the number of infants
becoming HIV-infected through their mothers from 400,000 to 240,000 between 2009 and 2013
(World Health Organization, 2014).
Global initiatives, including the World Health Organization’s (WHO) recommendation of
Option B+, lifelong HIV treatment for all pregnant women living with HIV, as the favoured strategy
in the prevention mother-to-child transmission (PMTCT) (WHO, 2012) have kept PMTCT high on
the international agenda. Option B+ also addresses the 2018 UNAIDS target to reach 95% of
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pregnant women living with HIV with sustained and lifelong HIV treatment, and to reduce the
annual number of newly infected children to less than 40,000 by the end of 2018 (UNAIDS,
2017). Option B+’s simplified approach to ART initiation reduces reliance on specialised laboratory
services to perform CD4 counts, it also reduces the risk of resistance from multiple ART initiations
among women in high-fertility settings (Kalua et al., 2017). Moreover, model-based studies, which
are typically based on normative guidance, estimated that in the long-run Option B+ would be more
cost-effective when compared to previous PMTCT mechanisms of Options A and B (Fasawe et al.,
2013; Gopalappa et al., 2014; Ishikawa et al., 2014).
The combination of global targets, and the rapid evolution in WHO guidance, drove the
widespread adoption of Option B+ for PMTCT. By 2015, 18 (of 21 countries in sub-Saharan
Africa deemed priority for PMTCT by UNAIDS) had moved to roll-out Option B+ (UNAIDS,
2015).
However, lifelong ART provision requires financial commitment from donors and govern-
ments for both the drugs and the accompanying support services required to ensure treatment
uptake and adherence. Empirical data on the per person costs of PMTCT services are there-
fore needed in order to estimate the level of commitment required, as well as to better utilise
existing resources to ensure programme sustainability. While the costs of PMTCT have been
documented in sub-Saharan African settings, most studies assess costs under previous ART
strategies, with few empirical estimates relating to Option B+ (Siapka et al., 2014). In particu-
lar, as ART coverage increases and the undiagnosed population falls, service delivery will need
to adapt to the issue that testing yields are falling and costs per case identified are going to
rise.
In 2013, the government of Tanzania rolled out Option B+, and by 2015, 84% of pregnant women
living with HIV were receiving lifelong ART (UNAIDS, 2017). Nine PMTCT service components are
outlined within the national policy including counselling and testing of all pregnant women and their
partners (unless they are already known to be HIV positive) during their first antenatal visit (Box 1)
(Ministry of Health, Community Development, Gender, Elderly, and Children (MoHCDGEC),
2017). For pregnant women who are HIV negative, repeat testing should be conducted during the
third trimester, or during labour and delivery. All breast-feeding mothers, unless known to be
HIV-positive, should be counselled and tested during breast-feeding. For those who were tested
during their third trimester, or at labour and delivery, a repeat HIV test should be offered at six
months after the first test, and thereafter as per the general population. Pregnant women living
with HIV and on ART should attend the antenatal care (ANC) clinic every month to be provided
with adherence and medication support. Finally, infants born to HIV mothers receive Nevirapine
prophylaxis, and undergo an HIV test at six weeks using deoxyribonucleic acid-polymerase chain
reaction (DNA-PCR) (known as early infant diagnosis (EID)) (Bwana et al., 2018; MoHCDGEC,
2017).
Box 1. Comprehensive approach to PMTCT in Tanzania: service components.
Service activity Description of core service activity contributing to comprehensive PMTCT approach
Routine HIV testing and
counselling
Identification of women/couples living with HIV so that they can receive PMTCT services and
HIV care, treatment and support.
Identification of women who are currently negative but at high risk for acquiring infections
during pregnancy and breast-feeding periods. Women/couples are encouraged to
continue using protective interventions.
Comprehensive ANC Monitor pregnancy progress and early detection and treatment of pregnancy-related
complications such as sexually transmitted infections and anaemia.
Provision of prevention of malaria and tuberculosis, and counselling to mothers on optimal
nutrition.
Provision of preventative medications such as Cotrimoxazole for Pneumonia.
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Lifelong ART for HIV positive pregnant and
breast-feeding women
Provision of ART to improve maternal health, which in turn improves child’s
survival chances. In addition, ART is provided to reduce maternal viral load,
which in turn reduces infant exposure to the virus and risk of mother to child
transmission.
ARV prophylaxis for HIV exposed infants Provision of ARV prophylaxis to reduce the chances of HIV-exposed infants
getting infected with HIV from their mother during the postpartum period.
Safer delivery practices Reduces likelihood of labour and delivery complications and infant exposure to
HIV during labour and delivery.
Counselling for safer infant feeding
practices
Promotion of safer infant feeding options to improve child survival and reduces
infant exposure to the virus, hence reducing mother to child transmission.
Postpartum care for the mother Support to mother’s health and nutrition status and addresses woman’s family
planning needs.
Early infant HIV diagnosis Identification of infants infected with HIV to initiate them on ART to improve
their survival.
Monitor and manage signs and symptoms of infection in children exposed to
HIV.
Ensure HIV early infant diagnosis and Cotrimoxazole for infants starting at 6
weeks of age
Infant treatment Ensure infant confirmatory testing after cessation of breast-feeding.
Facilitate early initiation of ART for HIV infected children
Partner and family involvement Identification of partners who are either HIV infected or who are at risk of being
infected (discordant).
Provision of HIV care, treatment and support to children and other family
members
Family planning Provision of counselling to both partners on family planning and dual
protection to reduce the risk of unintended pregnancy
Adapted from Ministry of Health, Social Welfare, Gender, Elder, and Children (2017, p. 110).
The public health system in Tanzania is made up of dispensaries, health centres, and district hospi-
tals and regional referral hospitals (Manzi et al., 2012). The majority of dispensaries and health
centres are publicly owned (76% and 67% respectively) and the rest are split between faith-based
and private ownership (MoHCDGEC, n.d.). Forty-six percent of hospitals are publicly owned,
40% are faith-based and the remaining 14% are privately owned (MoHCDGEC, n.d.). Over two-
thirds of Tanzania’s population reside in rural areas and primarily rely on dispensaries and health
centres, the most common type of facility, for health services (Manzi et al., 2012; MoHCDGEC,
2016). PMTCT was integrated into maternal and child health services such that PMTCT interven-
tions are delivered within facilities providing antenatal care, labour and delivery, and postnatal care.
This allows for the sharing of facility-level resources across different aspects of care and could have
an important role to play in keeping PMTCT service delivery costs low. In 2015, there were approxi-
mately 2 million births in Tanzania (UNICEF, 2017). The vast majority (98%) of pregnant women
attend ANC at least once (MoHCDGEC, 2016) although the majority attend in the second or third
trimester, and among these, 3% were either already HIV positive or tested HIV positive during their
ANC visit (Tanzania Commission for AIDS (TACAIDS), Zanzibar AIDS Commission (ZAC), 2018).
The aims of this study was to use a case study approach to estimate the costs of Option B+ inte-
grated into reproductive and sexual health services, and to explore cost variations across different
levels of health facilities in Tanzania.
Methods
Study setting
This study estimates the costs of PMTCT, under Option B+, delivered within routine maternal and
child health services, across12 health facilities serving the population of the Ifakara health and
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demographic surveillance system (HDSS) in Morogoro Region. The Ifakara HDSS was set up, among
other research objectives, to describe health system aspects of maternal, neonatal and child health
(Church et al., 2017; Geubbels et al., 2015). Since 2013, bi-annual health facility surveys have
been conducted in all 12 facilities providing HIV services to the HDSS population and with ≥100
patients per month in order to assess HIV service delivery. The Ifakara HDSS covers a geographic
area of 2400 km2 and monitors demographic events among a population of approximately
169,000 (125,000 in Ifakara Rural and 45,000 in Ifakara Urban), where HIV prevalence among adults
measured 7% (Church et al., 2017). This cost study was nested in the third round of the health facility
survey.
Health facility characteristics
Facilities were classified as dispensaries (n = 2) which only provide outpatient services; health centres
(n = 7) which offer both outpatient and inpatient services; and hospitals (n = 3) (Table 1). Ten facili-
ties were public (government-run), one was faith-based (hospital), and one was private-for-profit
(hospital). Two health centres had a delivery ward within the ANC unit, and labour and delivery
services were provided on site but in a separate room to other ANC services (but not within
ANC services) in the other eight facilities. No facility charged user fees for PMTCT services.
Cost study
The PMTCT services costed in this study were: (1) routine HIV testing and counselling using HIV
rapid diagnostic tests and including provision of both pre- and post-test counselling; (2) the pro-
vision of ART to pregnant women and mothers diagnosed with HIV according to national guide-
lines; and (3) neonatal HIV care which includes the provision of Nevirapine prophylaxis for
exposed infants and EID at 6 weeks using the DNA-PCR method (shaded areas in Box 1).
This study was undertaken from the health service providers’ perspective, and included both
financial cost estimates, resource inputs incurring actual expenditures, and economic cost estimates
i.e. donated items which were valued at their market price. The costing methodology drew on costing
guidelines for HIV prevention (UNAIDS, 2000) and followed standard principles (Drummond et al.,
1997; Vassall et al., 2018). A micro costing approach was applied which used a combination of top-
down and bottom up costing approaches to value resource use depending on the line item.
A standardised Excel-based instrument was used to record resource use and, where available,
record price information from each facility. Data were collected retrospectively for the 12 months
to September 2017. Fieldwork took place from October to December 2017. Resources were cate-
gorised into capital inputs e.g. buildings/room space, equipment and staff training; and recurrent
inputs e.g. staff and personnel, HIV test kits and supplies, ART, other clinical and non-clinical
supplies, and overheads.
Table 1. Facility characteristics.
Facility name Facility size/type Authority Inpatient care Labour & delivery
Dispensary A Small Public No N/A
Dispensary B Small Public No N/A
Health Centre C Small Public Yes Within facility
Health Centre D Small Public Yes Within ANC
Health Centre E Small Public Yes Within facility
Health Centre F Small Public Yes Within facility
Health Centre G Large Public Yes Within facility
Health Centre H Large Public Yes Within ANC
Large Health Centre I Large Public Yes Within facility
Hospital J Large Private-for-profit Yes Within facility
Hospital K Large Public Yes Within facility
Hospital L Large Faith-based Yes Within facility
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Service delivery data were captured from two sources: (1) Health Management Information Sys-
tems (HMIS); and (2) service use data from facility records e.g. registers and summary reports that
captured information on the delivery of HIV testing and counselling services, ANC services, and
ART services to the HDSS population – some of which were captured in the facility survey. Service
delivery data gathered from the HMIS included the number of pregnant or lactating women tested,
and the number who tested HIV-positive, the number who were initiated on ART, the total number
of PMTCT patients on ART, and the number of infants born to HIV-positive mothers who received
Nevirapine prophylaxis and/or tested for HIV at 6 weeks.
ART data obtained from the HMIS were limited because of a lack of disaggregation by ART regi-
mens which are priced differently. In order to estimate total ART drug costs, detailed ART data were
collected from two facilities (health centre C and hospital L) which included for each month: the
number of newly initiated patients, the total number of ART patients, ART regimen by patient,
and the number of months the patient was enrolled under PMTCT. The vast majority of patients
in health centre C (98%) and hospital L (91%) were recorded to be on the first-line ART regimen
Tenofovir + Lamivudine + Efavirenz (TDF+3TC + EFV), with the remaining on the alternative
first-line regimen Tenofovir + Emtricitabne + Efavarinz (TDF + FTC + EFV). In all other facilities,
the costs of ART were based on apportioning ART patients to regimens observed in health centre
C. This is because health centre C is more typical of health facilities in the region than hospital L
which is unique because it also conducts HIV research.
Recurrent costs: Health care worker salaries were obtained from the facilities and the amount of
time health workers spent on different HIV services was apportioned based on interviews with staff.
The number of HIV test kits used over the study timeframe was based on the number of PMTCT
patients tested. Prices for HIV test kits and ART supplies were obtained from the Global Fund
ART price and quality reporting list for 2017 (Global Fund, 2017). Where possible, the cost of uti-
lities and rent was gathered directly from the facilities, otherwise these costs were estimated using
data gathered from the commercial property in Ifakara. These costs were allocated to the different
HIV services based on the approximate proportion of staff time spent on those services. Prices of
diagnostic or laboratory tests (e.g. DNA-PCR) were obtained from Hospital L where HIV laboratory
services were provided to patients. Prices for other HIV supplies e.g. HIV testing and counselling
record books; ART cohort registers etc. were obtained from the National AIDS Control Programme.
Capital costs: All space used for the delivery of PMTCT services were audited and subsequently
valued using rental information (rent per square meter) from nearby commercial properties. Equip-
ment and furniture in spaces used to deliver PMTCT services were audited, and prices attributed
based on current replacement value, sourced through medical supplies catalogues and the National
AIDS Control Programme procurement office, and were annualised over 25 years using a 3% dis-
count rate. PMTCT training was provided by the Ministry of Health (MoH), the designated district
hospital (Hospital L), and the Boresha Afya programme funded by the United States Presidents
Emergency Plan For AIDS Relief. The cost per participant and per training schedule was obtained
from the training provided by the designated district hospital and used to estimate Boresha Afya and
MoH training costs. Training costs were annualised over 2 years using a 3% discount rate. Allocation
of capital costs (equipment) across the different HIV services (HIV testing, ART, and neonatal HIV
care) was based on interviews with staff on the approximate proportion of staff time spent on the
different HIV services.
Cost analysis
Facility survey data were analysed using STATA v15 and facility-level cost and outcome calculations
were undertaken using Microsoft Excel 2007. All costs were adjusted to 2017 United States dollars
(US$) and costs collected in Tanzanian Shillings (TZS) were converted to US$ using the average
exchange rate from October 2016 to September 2017: 1 US$ = 2250 TZS (Oanda, 2018). Total
costs and average (unit) costs were calculated for each facility and for the following PMTCT services:
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(1) HIV testing: The cost per testing episode, based on the full testing algorithm for pregnant and
lactating women (which may include confirmatory testing if carried out) and per patient diag-
nosed with HIV were calculated by dividing the total facility costs of running testing services in
one year by the number of testing episodes and the number of HIV-positive individuals ident-
ified over the same timeframe, respectively.
(2) ART: The annual cost per PMTCT patient in ART care was calculated by dividing the total
annual costs of providing care and treatment services by the number of HIV patients receiving
it.
(3) Neonatal HIV care: The cost per exposed infant born receiving Nevirapine prophylaxis and/or
tested for HIV at 6 weeks using DNA-PCR test was estimated by dividing the total costs of test-
ing infants for HIV and provision of Nevirapine by the total number of exposed infants born.
A one-way sensitivity analysis was undertaken to understand how a +/- 10% variation in staffing
levels, and prices of HIV test kits, ART, and DNA-PCR, affected the costs of each of the HIV services.
Ethics
Ethical clearance was provided by the National Institute of Medical Research, United Republic of
Tanzania (NIMR/HQ/R.8a/Vol. IX /2579), and the London School of Hygiene and Tropical Medi-
cine, United Kingdom (REF: 13536).
Results
PMTCT service delivery
PMTCT service delivery data are presented in Table 2. HIV testing and counselling services were
provided at least five days per week in all 12 facilities. Across all facilities, 66 health workers provided
PMTCT of whom 48.5% (n=32) staff members had received training on PMTCT in the two years
prior to the data collection. An estimated 23 full time equivalent (FTE) staff members provided
HIV testing, as in the integrated model of delivery staff time was spent on other activities as well
as HIV services.
A total of 25,593 HIV testing episodes were reported over the 12 months averaging 2,133 testing
episodes per facility; range702 (Hospital J) to 4452 (Health Centre I). This translated to approxi-
mately 4.6 tests per FTE testing staff member per day (assuming 240 working days per year);
range 1.2 tests per FTE staff (Hospital L) to 18.6 tests per FTE staff (Health Centre I). The annual
positivity rate averaged 1.1%; range 0.2% (Health Centre F) to 2.0% (Health Centre E).
The staff interviews found that the total number of FTE health workers providing HIV care and
treatment was 13.9. At the end of the study period (September 2017), a total of 1,019 pregnant or
lactating women were taking ART, of whom 278 (27.3%) had been newly initiated on ART during
the 12-month study timeframe. ART initiation was reported to take place on the same day as a
patient tested positive in eleven facilities, and the day after testing in one facility (Hospital L).
The number of HIV exposed infants born during the study period totalled 372; range 1 (Dispen-
sary A) to 122 (Hospital L). Of these, 73% (n = 287) received neonatal HIV care (Nevirapine and/or
HIV test at 6 weeks using DNA-PCR), and 2% (n = 6) were diagnosed to be infected with HIV.
PMTCT service delivery costs
The annual cost of HIV testing totalled US$140,419; range US$3,012 (Dispensary A) to US$27,392
(Hospital L) (Table 3). The average annual cost per PMTCT client testing episode was US$5.49;
range US$2.13 (Health Centre I) to US$13.93 (Hospital L). The average cost per PMTCT client
who tested HIV-positive was US$503.29; range US$230.61 (Health Centre G) to $3330.38 US
6 S. VYAS ET AL.































HIV at 6 wks
Dispensary A 2 0.4 1 748 7 0.9 0.2 43 19 6 7 2
Dispensary B 5 1.3 0 2237 14 0.6 0.4 31 13 1 1 0
Health Centre C 5 2.3 3 3518 63 1.8 0.4 169 62 73 61 1
Health Centre D 5 2 2 1530 10 0.7 0.8 29 11 12 12 0
Health Centre E 10 2.5 4 1420 29 2.0 1 68 29 29 29 0
Health Centre F 6 1 3 2375 4 0.2 0.4 17 7 4 4 2
Health Centre G 3 1.3 3 1874 32 1.7 0.5 76 29 36 32 0
Health Centre H 12 2 4 3296 55 1.7 0.8 149 59 44 35 0
Health Centre I 2 1 3 4452 21 0.5 0.4 30 11 7 6 0
District Hospital J 2 1 3 702 2 0.3 0.4 4 1 5 5 0
District Hospital K 3 1.5 1 1475 18 1.2 0.6 52 18 33 33 0
Reg./Ref. Hospital L 11 7 5 1966 24 1.2 8 351a 19 122 62 1
Total 66 23.2 32 25,593 279 1.1% 13.9 1019 278 372 287 6
Average 5.5 1.9 2.7 2,133 23.3 1 85 23 31 24 0.5










(Hospital J). In each facility, staff time was the main cost driver of HIV testing services accounting
for, on average, 79.2% of total HIV testing service costs, ranging from 55.1% (Health Centre I) to
88.9% (Hospital L) (Figure 1). This was followed by HIV test kits which accounted for, on average,
15.3% of total costs, ranging from 6.0% (Hospital L) and 38.8% (Health Centre I).
Figure 2(a,b) indicates that there are likely to be inverse relationships between the cost per testing
episode and the number of testing episodes conducted (Figure 2(a)) as well as between the HIV posi-
tivity rate and the cost per HIV case diagnosed (Figure 2(b)). Moreover, the cost per testing episode
in hospitals is more than twice that in dispensaries and health centres: US$10,52; US$4.77; and US
$4.47 respectively. The cost per HIV case diagnosed is also higher in hospitals compared with dis-
pensaries and health centres: US$990.90; US$678.06; and US$385.89 respectively.
The total cost of delivering ART to pregnant and lactating women was US$162,930 averaging US
$13,578 per facility; range US$3,249 (Hospital J) to US$70,563 (Hospital L) (Table 4). The average
cost per PMTCT patient year was US$159.89, however there was variation in average cost across the
12 facilities; ranging from US$100.91 (Health centre C) to US$812.23 US (Hospital J). This variation
in costs was driven by differences in personnel costs which, on average, accounted for 42% of total
costs.
Table 3. Mean and range of annual facility level HIV service testing costs across 12 facilities in Tanzania, in 2017 US$.
Total US$ Min Max US$ per test Min Max US$ per HIV Min Max
Building 4,114 94 583 0.16 0.03 0.59 14.75 1.70 205.56
Equipment 299 9 53 0.01 0.00 0.03 1.07 0.54 13.22
Training 414 0 142 0.02 0.00 0.20 1.48 0.00 71.11
Total capital 4,827 181 662 0.19 0.05 0.80 17.30 3.29 281.09
Personnel 111,230 2,091 24,339 4.35 1.17 12.38 398.67 163.33 2613.34
Test kits 21,433 579 3,684 0.84 0.82 0.85 76.82 41.75 488.48
Other supplies 175 6 31 0.01 0.01 0.01 0.63 0.32 3.83
Utilities & other 2,755 61 873 0.11 0.03 0.44 9.87 3.39 143.47
Total recurrent 135,592 2,782 26,875 5.30 2.04 13.67 485.99 218.37 3049.29
Total 140,419 3,012 27,392 5.49 2.13 13.93 503.29 230.61 3330.38
Figure 1. Average cost per testing episode for PMTCT HIV testing and breakdown of costs by resource input in 2017 US$.
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The costs for the provision of neonatal HIV care are shown in Table 5. The total cost across
all 12 facilities was US$25,857; range US$174 (Dispensary A) to US$11,176 (Hospital L). Recur-
rent costs contributed to the majority of total costs e.g. personnel, which accounted for 58% of
total costs, and DNA-PCR tests, which accounted for 36% of total costs. The average cost of neo-
natal HIV care per infant was US$90.09; ranging from US$41.53 (Health Centre C) to US$180.26
(Dispensary B).
Figure 2. (a) Number of testing episodes and cost per testing episode for mothers within PMTCT services in 12 health care facilities
in Tanzania (2017 US$). (b) HIV positivity rate and cost per HIV case diagnosed within PMTCT services in 12 health care facilities in
Tanzania (2017 US$).
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Sensitivity analysis
When staff inputs were varied by ±10% across the three HIV services, the mean cost per person diag-
nosed with HIV changed by ±8% and ranged from $463.43 to $543.16 (Table 6). The mean cost per
PMTCT patient-year resulted in a ±4% change; range $153.16 to $166.63, and the mean cost per
neonatal care resulted in ±6% change; range $84.90 to $95.29. Varying the price of HIV test kits
by ±10% resulted in a ±2% change in the mean cost per person diagnosed with HIV, and the
mean cost per PMTCT patient-year changed by ±5% when ART prices where varied by ±10%.
Finally, varying the price of DNA-PCR test resulted in a ±4% change in the mean cost per neonatal
care.
Discussion
This study estimated the cost of PMTCT services in 12 facilities in Morogoro Region, Tanzania. The
study is one of few to estimate costs along the PMTCT service cascade, with previous studies having
focused on either testing or on care and treatment services. Our findings are also unique for sub-
Table 5. Total facility costs of providing neonatal HIV care (Nevirapine and HIV test at 6 weeks using DNA-PCR) (mean and range)
across 12 facilities in Tanzania, in 2017 US$.
Total US$ Min Max US$ per infant Min Max
Building 388 5 55 1.35 0.14 33.78
Equipment 23 0 3 0.08 0.01 1.71
Training 459 0 142 1.60 0.00 28.45
Total capital 870 23 198 3.03 1.10 39.64
Personnel 14,912 107 7,749 51.96 8.57 130.67
Nevirapine 465 1 153 1.62 1.07 2.46
DNA-PCR 9,300 25 3,050 32.40 21.43 49.19
Other supplies 50 0 16 0.17 0.11 0.26
Utilities & other 261 2 109 0.91 0.23 7.65
Total recurrent 24,987 138 11,077 87.06 40.37 178.66
Total cost 25,857 174 11,176 90.09 41.53 180.26
Table 6. Sensitivity analysis results and change in average cost by HIV service, in 2017 US$.
HIV service Metric: cost per Parameter Range: US$ % Change in cost
HIV testing HIV case diagnosed Personnel 463.43 543.16 ±8%
HIV test kits 495.61 510.98 ±2%
PMTCT PMTCT patient year on ART Personnel 153.16 166.63 ±4%
ART 151.98 167.80 ±5%
Neonatal care Neonatal HIV infant care Personnel 84.90 95.29 ±6%
DNA-PCR 86.85 93.34 ±4%
Table 4. The average annual facility cost of ART among pregnant and lactating women (mean and range) across 12 facilities in
Tanzania, in 2017 US$.
Total US$ Min Max US$ per patient year Min Max
Building 2,666 29 1,518 2.62 0.41 27.41
Equipment 164 2 72 0.16 0.05 0.59
Training 2,069 26 621 2.03 0.50 155.16
Total capital 4,899 60 1,848 4.81 1.39 183.15
Personnel 68,615 1,045 37,639 67.34 12.37 522.67
ART 80,586 316 27,758 79.08 79.08 79.08
CPT prophylaxis 7,439 29 2,562 7.30 7.30 7.30
Other supplies 173 4 50 0.17 0.14 0.90
Utilities & other 1,219 9 705 1.20 0.21 19.13
Total recurrent 158,031 2,516 68,715 155.08 99.24 629.08
Total cost 162,930 3,249 70,563 159.89 100.91 812.23
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Saharan Africa as they include data from multiple sites with different characteristics allowing for an
exploration of how size of the facility might drive costs. In addition, our analysis is based on all facili-
ties, covering a large geographic area, which provide HIV services to a HDSS population, and which
broadly reflects the health system nationally. The cost per HIV diagnosis ranged from US$230.61 to
US$3330.38; the cost of care and treatment for positive pregnant and lactating women ranged from
US$100.91 to US$812.23 and the cost of neonatal HIV care per HIV exposed infant ranged from US
$41.53 to US$180.26. This contribution to the evidence base is invaluable for planning purposes and
for showing how future budgets and programmes need to account for such cost variations and to
optimise current funding.
The large variations in average costs for the different components of the care cascade across the
facilities may suggest implementation inefficiencies across the different facilities, or that geographical
or other factors require different levels of investment. For HIV testing and for neonatal HIV care,
personnel was the main cost driver. For care and treatment of mothers, ART drugs were the
main cost driver but not for all facilities. For HIV testing, we observed variation across the facilities
in both the average cost per testing episode and the average cost per HIV case diagnosed. The average
cost of an HIV testing episode amounted to $5.49 across all 12 facilities and ranged from $2.13 to
$13.93. Estimates of PMTCT costs from earlier studies in east and southern Africa countries are
higher than the costs presented here. For example, a four country study, conducted in 2012, esti-
mated the average annual cost per facility-based PMTCT client tested for HIV ranged from US
$18 (SD US$20) in Rwanda to US$89 (SD US$56) in South Africa (Bautista-Arredondo et al.,
2016). This variation might be the result of cross-country variation but might also be a reflection
of changing costs as PMTCT programmes have evolved over time.
The average cost per PMTCT patient diagnosed was US$503.29 (including pre- and post-test
counselling) with large variation across the facilities, and likely driven by the HIV positivity rate.
Despite, the wide range, this estimate is comparable with that found by Bautista-Arredondo et al.
(2016), who found the average cost per PMTCT client diagnosed as HIV-positive ranged from
US$565 in Zambia to US$2021 in Rwanda. As found in this study, the authors identified that per-
sonnel was the key cost driver of PMTCT testing services, and, therefore, cross-country salary differ-
ences could explain the lower costs in Tanzania. For example, the average annual salary for a nurse in
our sample was approximately US$5,250, slightly lower than documented in Rwanda (US$6,259)
and considerably lower than that documented in Zambia (US$15,736) and South Africa ($33,976
US) (Bautista-Arredondo et al., 2016). In addition, in this study it was found that not all testing per-
sonnel spent 100% of their time on HIV services. This sharing of personnel across different services is
an important element of how the integrated model has potential to increase efficiency without lower
quality of services.
The average cost per patient year of providing ART for PMTCT was US$159.89 and ranged from
US$100.91 to US$812.23. To date, few studies have empirically estimated the costs of PMTCT under
Option B+, with existing studies using modelled-based approaches to demonstrate cost-effectiveness
of Option B+ over prior PMTCT strategies (Karnon & Orji, 2016). To date, only two recently pub-
lished studies, from Ethiopia and Eswatini, have estimated PMTCT treatment costs under Option B
+. The study in Ethiopia collected data for 2013-2014, and found the unit cost (in 2014 US$) per
pregnant woman-infant pair per year averaged US$701 US (SD US$324) in urban health facilities
and US$302 (SD US$53) in rural health facilities (Zegeye et al., 2019). In Eswatini, cost data were
collected from 2013 to 2015 and the researchers estimated the cost (in 2015 US$) per PMTCT patient
treated per month was US$183 (Cunnama et al., 2018). These studies measure the costs of different
units of PMTCT services to the study presented here so it is difficult to make direct comparisons. For
example, the study in Ethiopia considers PMTCT as a whole (i.e. costed HIV testing, treatment and
EID together), while the study in Eswatini was conducted during a period of transition to Option B+
and therefore, included Option B+ start-up and training costs. Finally, this study estimated the cost
of neonatal HIV care per exposed infant was US$90.09 and ranged fromUS$41.53 to US$180.26.
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With few infants testing HIV positive at 6 weeks, this study did not seek to estimate the cost per
infant diagnosed with HIV.
There are several limitations of this study that are important to note. Firstly, the study only cap-
tures data on a subset of core PMTCT services for pregnant women living with HIV, and critical
steps following HIV diagnosis and enrolment in care, such as safer delivery practices and counselling
for safer infant feeding practices, were not disaggregated. Linked with this point, the study estimates
costs from a provider perspective and did not include direct costs to patients – a cost which might be
crucial to consider in HIV treatment given the wide geographic and remote spread of these facilities
which may hamper patient access. Thirdly, we relied on provider interviews, rather than direct
observation, to measure and allocate staff time, and this may be subject to over-estimation of health
worker contact time with patients (Bratt et al., 1999). Finally, because of data unavailability, this
study did not capture information on essential above service delivery activities, that is activities coor-
dinated at national and district levels which are essential for the delivery of HIV services, such as
quality assurance and audits. Nevertheless, these findings are important because they are among
the few studies to cost PMTCT along the service cascade which increases the evidence base for future
cost projections, and provide us with a detailed understanding of the cost drivers in Option B+. Esti-
mates of costs of PMTCT in Tanzania are scarce, and this study provides much needed guidance to
policy makers on how to better target PMTCT services.
PMTCT costs in Tanzania vary across different types of health facilities and scale of operation.
Hospitals, on average, had higher average costs than the health centres and dispensaries, and a
weak inverse relationship between output and unit cost was observed per HIV case diagnosed. Per-
sonnel costs were confirmed as a key cost driver in Option B+, supporting the integrated care model
that has been adopted in Tanzania. With a high birth rate alongside a declining HIV positivity rate,
as the Option B+ programme matures and global efforts to achieve elimination of mother-to-child
transmission, the average per case diagnosed within PMTCT services will likely increase. The inte-
grated model provides a way to minimise these costs by allowing non-specific resources to be shared
across a range of services. Careful planning in the allocation of resources, especially personnel, will be
needed to ensure value for money when meeting this increased demand.
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